EP2035417 - BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 06.01.2012 Database last updated on 31.08.2024 | Most recent event Tooltip | 04.10.2013 | Lapse of the patent in a contracting state New state(s): HU | published on 06.11.2013 [2013/45] | Applicant(s) | For all designated states AstraZeneca AB 151 85 Södertälje / SE | [2009/12] | Inventor(s) | 01 /
BIRCH, Alan Martin AstraZeneca R & D Alderley Alderley Park Macclesfield Cheshire SK10 4TG / GB | 02 /
BUTLIN, Roger John AstraZeneca R & D Alderley Alderley Park Macclesfield Cheshire SK10 4TG / GB | 03 /
PLOWRIGHT, Alleyn AstraZeneca R & D Mölndal 431 83 Mölndal / SE | [2009/12] | Representative(s) | Berry, Ian Gordon AstraZeneca AB Global Intellectual Property 151 85 Södertälje / SE | [2009/12] | Application number, filing date | 07733082.7 | 06.06.2007 | [2009/12] | WO2007GB02070 | Priority number, date | US20060811895P | 08.06.2006 Original published format: US 811895 P | [2009/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2007141517 | Date: | 13.12.2007 | Language: | EN | [2007/50] | Type: | A1 Application with search report | No.: | EP2035417 | Date: | 18.03.2009 | Language: | EN | The application published by WIPO in one of the EPO official languages on 13.12.2007 takes the place of the publication of the European patent application. | [2009/12] | Type: | B1 Patent specification | No.: | EP2035417 | Date: | 02.03.2011 | Language: | EN | [2011/09] | Search report(s) | International search report - published on: | EP | 13.12.2007 | Classification | IPC: | C07D413/04, C07D413/14, A61K31/4245, A61P3/10 | [2009/12] | CPC: |
C07D413/04 (EP,KR,US);
A61K31/4245 (KR);
A61P1/04 (EP);
A61P13/12 (EP);
A61P15/08 (EP);
A61P17/02 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P19/10 (EP);
A61P21/00 (EP);
A61P25/00 (EP);
A61P25/28 (EP);
A61P27/02 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P31/18 (EP);
A61P37/02 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/04 (EP);
A61P9/08 (EP);
A61P9/10 (EP);
C07D413/14 (EP,KR,US)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/12] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | 08.01.2009 | MK | Not yet paid | RS | Not yet paid | Title | German: | BENZIMIDAZOLE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON DIABETES | [2009/12] | English: | BENZIMIDAZOLES AND THEIR USE FOR THE TREATEMNT OF DIABETES | [2009/12] | French: | BENZIMIDAZOLES ET LEUR APPLICATION AU TRAITEMENT DU DIABÈTE | [2009/12] | Entry into regional phase | 08.01.2009 | National basic fee paid | 08.01.2009 | Designation fee(s) paid | 08.01.2009 | Examination fee paid | Examination procedure | 08.01.2009 | Examination requested [2009/12] | 23.03.2010 | Despatch of a communication from the examining division (Time limit: M04) | 28.06.2010 | Reply to a communication from the examining division | 18.10.2010 | Communication of intention to grant the patent | 20.01.2011 | Fee for grant paid | 20.01.2011 | Fee for publishing/printing paid | Opposition(s) | 05.12.2011 | No opposition filed within time limit [2012/06] | Fees paid | Renewal fee | 30.06.2009 | Renewal fee patent year 03 | 30.06.2010 | Renewal fee patent year 04 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AT | 02.03.2011 | BE | 02.03.2011 | CY | 02.03.2011 | CZ | 02.03.2011 | DK | 02.03.2011 | EE | 02.03.2011 | FI | 02.03.2011 | HU | 02.03.2011 | LT | 02.03.2011 | LV | 02.03.2011 | MT | 02.03.2011 | PL | 02.03.2011 | RO | 02.03.2011 | SI | 02.03.2011 | SK | 02.03.2011 | BG | 02.06.2011 | GR | 03.06.2011 | IE | 06.06.2011 | LU | 06.06.2011 | MC | 30.06.2011 | IS | 02.07.2011 | PT | 04.07.2011 | [2013/45] |
Former [2013/25] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
DK | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
MT | 02.03.2011 | ||
PL | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IE | 06.06.2011 | ||
LU | 06.06.2011 | ||
MC | 30.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
Former [2013/21] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
DK | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
MT | 02.03.2011 | ||
PL | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IE | 06.06.2011 | ||
MC | 30.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
Former [2012/20] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
DK | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
MT | 02.03.2011 | ||
PL | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IE | 06.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
Former [2012/12] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
DK | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
MT | 02.03.2011 | ||
PL | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
Former [2012/05] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
MT | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
PL | 20.07.2011 | ||
Former [2011/50] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
IS | 02.07.2011 | ||
PT | 04.07.2011 | ||
PL | 20.07.2011 | ||
Former [2011/49] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
CZ | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
RO | 02.03.2011 | ||
SI | 02.03.2011 | ||
SK | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
PT | 04.07.2011 | ||
Former [2011/47] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
EE | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
SI | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
PT | 04.07.2011 | ||
Former [2011/41] | AT | 02.03.2011 | |
BE | 02.03.2011 | ||
CY | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
SI | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
Former [2011/38] | AT | 02.03.2011 | |
CY | 02.03.2011 | ||
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
SI | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
Former [2011/37] | CY | 02.03.2011 | |
FI | 02.03.2011 | ||
LT | 02.03.2011 | ||
LV | 02.03.2011 | ||
SI | 02.03.2011 | ||
BG | 02.06.2011 | ||
GR | 03.06.2011 | ||
Former [2011/36] | LT | 02.03.2011 | |
LV | 02.03.2011 | ||
GR | 03.06.2011 | Cited in | International search | [A]US2003072757 (FARESE ROBERT V [US], et al) [A] 1-9 * example -; claim - *; | [DA]WO2004047755 (TULARIK INC [US], et al) [DA] 1-9 * page 1, paragraph 1 - page 3, paragraph 9; example -; claim - *; | [DA]WO2004100881 (BAYER PHARMACEUTICALS CORP [US], et al) [DA] 1-9 * page 1, line 1 - page 2, line 2; example -; claim - *; | [A]US2005070545 (FOX BRIAN M [US], et al) [A] 1-9 * page 1, paragraph 2 - paragraph 7; example -; claim - *; | [PA]WO2006064189 (ASTRAZENECA AB [SE], et al) [PA] 1-9* page 1 - page 2; example -; claim - *; | [PA]WO2006134317 (ASTRAZENECA AB [SE], et al) [PA] 1-9 * page 1 - page 2; example -; claim - *; | [A] - S. N. SAWHNEY ET. AL., "Synthesis of some 2-(5-substituted 1,3,4-oxadiazol-2-yl)-, 2-(5-substituted 1,3,4-thiadiazol-2-yl)- and 2-(3-mercapto-4-substituted- 4H-1,2,4-triazol-5-yl)- benzimidazoles as potential antiinflammatory agents.", INDIAN JOURNAL OF CHEMISTRY SECTION B, (1991), vol. 30B, pages 407 - 412, XP009089706 [A] 1-9 * page 407, formula III; page 411, table 2, compounds IIId and IIIe * | by applicant | JP2004067635 | WO2004047755 | WO2004100881 | WO2005013907 | - SMITH, "Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking DGAT", NATURE GENETICS, (2000), vol. 25, pages 87 - 90 | - CHEN, "Increased insulin and leptin sensitivity in mice lacking acyl CoA:diacylglycerol acyltransferase", J. CLIN. INVEST, (2002), vol. 109, pages 1049 - 1055 | - J. CLIN. INVEST., vol. 111, pages 1715 - 1722 | - SAWHNEY; GUPTA, INDIAN JOURNAL OF CHEMISTRY, (1991), vol. 30B, pages 407 - 412 | WO2005GB04726 |